Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Phase 3 Development & Timeline Orforglipron's Phase 3 clinical development program is one of the most comprehensive in the history of obesity and diabetes pharmacotherapy, encompassing multiple trials across two parallel programs: the ATTAIN series for obesity indications and the ACHIEVE series for type 2 diabetes
However, your body is unique, and so are your weight loss goals
Splitting the weekly dose can reduce peak concentration by roughly 28% twice weekly, or 35% three times weekly , per the pharmacokinetic modeling in our companion guide
02/26/14 - Added section on parallel vs
& Fire, A
US$ 20.68
US$ 27.39
US$ 23.36
US$ 24.30
US$ 24.71
